Abbott Announces Nutrition Business Spin-off to Focus on High-Margin Medical Technologies

During its third quarter 2026 earnings call, Abbott (ABT) announced a strategic plan to spin off its nutrition business into an independent public company. This structural shift aims to transition the remaining enterprise into a pure-play medical technology and diagnostics firm, focusing on higher-margin sectors such as electrophysiology and precision oncology. The company reported strong momentum in its diagnostic segment, highlighted by 14% growth in cancer diagnostics driven by colorectal screening tools. Additionally, Abbott's medical device segment is seeing acceleration through new pulsed field ablation technologies in cardiac care. Management expects this reorganization to accelerate overall sales growth rates and expand profit margins while maintaining dividend continuity.

5 articles from 4 sources · updated

Coverage